# Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis

Study · id `cardio:ct-nct07908225` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07908225](<https://clinicaltrials.gov/study/NCT07908225>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07908225

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 150 participants.

## Technical summary

Registry record NCT07908225. Allocation not applicable; no masking; primary purpose treatment. Start 2021-09-10 (actual); primary completion 2024-02-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT07908225, source copy `cardio:ctgov-nct07908225-2026-11-02`, retrieved 2026-11-18)
- Started: 2021-09-10 (actual) (ClinicalTrials.gov record NCT07908225, source copy `cardio:ctgov-nct07908225-2026-11-02`, retrieved 2026-11-18)
- Primary completion: 2024-02-29 (actual) (ClinicalTrials.gov record NCT07908225, source copy `cardio:ctgov-nct07908225-2026-11-02`, retrieved 2026-11-18)
- Completion: 2028-02-29 (anticipated) (ClinicalTrials.gov record NCT07908225, source copy `cardio:ctgov-nct07908225-2026-11-02`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07908225, source copy `cardio:ctgov-nct07908225-2026-11-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07908225-2026-11-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
- Condition: Aortic Stenosis
- Intervention (Device): TAVR
- Lead sponsor: Peijia Medical Technology (Suzhou) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Peijia Medical Technology (Suzhou) Co., Ltd. (`cardio:org-peijia-medical-technology-suzhou-co-ltd`)

## Provenance

Content hash: dd0648adbf955ae889738cb513fdd1a7436aa44f884830a115daf1fd422d0ab9
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
